In yesterday’s Wall Street session, Pacific Biosciences of California Inc (NASDAQ:PACB) shares traded at $3.41, down -6.58% from the previous session.
PACB stock price is now -36.30% away from the 50-day moving average and -61.05% away from the 200-day moving average. The market capitalization of the company currently stands at $913.71M.
With the price target of $11, Stephens recently initiated with Overweight rating for Pacific Biosciences of California Inc (NASDAQ: PACB). , while ‘Wolfe Research’ rates the stock as ‘Peer Perform’
In other news, Meline David W, Director bought 40,000 shares of the company’s stock on Mar 06 ’24. The stock was bought for $176,160 at an average price of $4.40. Upon completion of the transaction, the Director now directly owns 40,000 shares in the company, valued at $0.14 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 04 ’24, HENRY CHRISTIAN O sold 14,177 shares of the business’s stock. A total of $69,056 was realized by selling the stock at an average price of $4.87. This leaves the insider owning 2,596,670 shares of the company worth $8.85 million. A total of 6.09% of the company’s stock is owned by insiders.
During the past 12 months, Pacific Biosciences of California Inc has had a low of $3.45 and a high of $14.55. As of last week, the company has a debt-to-equity ratio of 1.33, a current ratio of 7.81, and a quick ratio of 7.21. The fifty day moving average price for PACB is $5.2012 and a two-hundred day moving average price translates $8.5379 for the stock.
The latest earnings results from Pacific Biosciences of California Inc (NASDAQ: PACB) was released for Dec, 2023. According to the Medical Devices Company, earnings per share came in at -$0.31, missing analysts’ expectations of -$0.28 by -0.03. This compares to -$0.37 EPS in the same period last year. The net profit margin was -152.97% and return on equity was -48.53% for PACB. The company reported revenue of $58.36 million for the quarter, compared to $27.35 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 113.35 percent. For the current quarter, analysts expect PACB to generate $50.39M in revenue.
